IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 84 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $46,416,921 | -43.1% | 5,786,532 | +5.1% | 0.00% | -50.0% |
Q1 2024 | $81,619,881 | +99.3% | 5,506,617 | +9.3% | 0.01% | +100.0% |
Q4 2023 | $40,956,054 | +89.5% | 5,037,098 | +6.1% | 0.00% | +33.3% |
Q3 2023 | $21,612,338 | -25.8% | 4,749,411 | +14.8% | 0.00% | 0.0% |
Q2 2023 | $29,134,077 | +56.9% | 4,138,362 | +36.2% | 0.00% | +50.0% |
Q1 2023 | $18,570,944 | +103463.1% | 3,039,433 | +8.3% | 0.00% | -33.3% |
Q4 2022 | $17,932 | -99.9% | 2,806,381 | +5.0% | 0.00% | -25.0% |
Q3 2022 | $25,599,000 | -12.2% | 2,672,158 | +1.2% | 0.00% | 0.0% |
Q2 2022 | $29,144,000 | -7.8% | 2,639,889 | +39.1% | 0.00% | 0.0% |
Q1 2022 | $31,604,000 | -10.4% | 1,898,187 | +2.7% | 0.00% | 0.0% |
Q4 2021 | $35,274,000 | -19.9% | 1,847,811 | +3.5% | 0.00% | -33.3% |
Q3 2021 | $44,043,000 | -7.5% | 1,786,012 | -2.4% | 0.01% | -14.3% |
Q2 2021 | $47,596,000 | -12.7% | 1,829,236 | +6.2% | 0.01% | -12.5% |
Q1 2021 | $54,544,000 | -29.2% | 1,722,823 | +3.8% | 0.01% | -38.5% |
Q4 2020 | $77,017,000 | +49.5% | 1,659,861 | +6.1% | 0.01% | +30.0% |
Q3 2020 | $51,519,000 | +17.2% | 1,564,985 | -2.3% | 0.01% | +11.1% |
Q2 2020 | $43,950,000 | -17.2% | 1,601,146 | -9.7% | 0.01% | -35.7% |
Q1 2020 | $53,055,000 | -42.2% | 1,772,369 | -46.5% | 0.01% | +40.0% |
Q4 2019 | $91,734,000 | +219.1% | 3,314,116 | +109.8% | 0.01% | +42.9% |
Q3 2019 | $28,744,000 | -28.2% | 1,579,401 | -3.3% | 0.01% | -30.0% |
Q2 2019 | $40,030,000 | +185.7% | 1,632,556 | +10.8% | 0.01% | +150.0% |
Q1 2019 | $14,012,000 | -41.1% | 1,473,408 | -45.2% | 0.00% | 0.0% |
Q4 2018 | $23,800,000 | +140.8% | 2,689,404 | +206.1% | 0.00% | +33.3% |
Q3 2018 | $9,882,000 | +1.6% | 878,484 | +15.5% | 0.00% | 0.0% |
Q2 2018 | $9,731,000 | -12.3% | 760,308 | +15.8% | 0.00% | -25.0% |
Q1 2018 | $11,098,000 | +141.7% | 656,714 | +14.4% | 0.00% | +100.0% |
Q4 2017 | $4,592,000 | +12.9% | 574,043 | +9.4% | 0.00% | 0.0% |
Q3 2017 | $4,067,000 | +6.9% | 524,892 | +1.4% | 0.00% | +100.0% |
Q2 2017 | $3,804,000 | – | 517,648 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 3,019,201 | $26,720,000 | 20.38% |
Broadfin Capital, LLC | 5,951,153 | $52,668,000 | 6.92% |
GREAT POINT PARTNERS LLC | 5,567,348 | $49,271,000 | 6.23% |
Avoro Capital Advisors LLC | 10,261,039 | $90,810,000 | 5.43% |
FRAZIER MANAGEMENT LLC | 2,188,331 | $19,367,000 | 5.00% |
Prosight Management, LP | 1,062,500 | $9,403,000 | 4.85% |
Perceptive Advisors | 12,241,111 | $108,333,000 | 4.12% |
Ghost Tree Capital, LLC | 1,000,000 | $8,850,000 | 3.21% |
QVT Financial LP | 1,021,361 | $8,696,000 | 2.84% |
Vivo Capital, LLC | 1,600,000 | $14,160,000 | 1.81% |